Some of the BCL2 inhibitors, such as ABT737, ABT263, and ABT199, had efficient clinical relevance; however, ABT737 and ABT263 were eliminated due to dose-limiting toxicities, including neutropenia and thrombocytopenia4,19. Here, BCL2 is linked to neutropenia.